FDA Clears Imfinzi as First Perioperative Immunotherapy for Resectable Gastric and GEJ Cancers | iPharmaCenter

19 hours ago

FDA Greenlights Kygevvi as Pioneering Therapy for Thymidine Kinase 2 Deficiency in Adults and Kids | iPharmaCenter

4 days ago

Novartis Receives FDA Approval for Itvisma, Expanding Access to Gene Replacement Therapy for People of All Ages Living with Spinal Muscular Atrophy (SMA)

Nov 25

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

Nov 23

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

Nov 19

FDA Approves Novartis' Pluvicto for Earlier Treatment of Prostate Cancer | iPharmaCenter

Apr 3

Tevimbra Receives U.S. Approval for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy | iPharmaCenter

Mar 5

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

Feb 3

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

Jan 29

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

Jan 3

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

Dec 23, 2024

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

Oct 13, 2024